What is HC Wainwright's Estimate for TRVI FY2024 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a research note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.48) per share for the year, up from their prior forecast of ($0.49). HC Wainwright has a "Buy" rating and a $12.50 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics' Q1 2025 earnings at ($0.11) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at ($0.30) EPS.

Several other research firms have also recently commented on TRVI. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Friday, March 7th. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Finally, Needham & Company LLC increased their price target on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $15.94.

Remove Ads

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock traded down $0.21 during midday trading on Thursday, hitting $6.54. The company had a trading volume of 1,950,663 shares, compared to its average volume of 955,160. The company has a 50 day moving average of $4.35 and a 200 day moving average of $3.63. The stock has a market capitalization of $502.70 million, a P/E ratio of -14.86 and a beta of 0.90. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now owns 76,900 shares of the company's stock, valued at $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 24.37% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. increased its stake in Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company's stock worth $336,000 after acquiring an additional 69,167 shares during the last quarter. Geode Capital Management LLC raised its holdings in Trevi Therapeutics by 10.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company's stock valued at $4,223,000 after buying an additional 117,418 shares during the period. Barclays PLC lifted its position in Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company's stock worth $319,000 after buying an additional 61,317 shares during the last quarter. State Street Corp boosted its stake in Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company's stock worth $3,183,000 after buying an additional 53,051 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after buying an additional 6,764 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.